Medical University of South Carolina

Institutional Biosafety Committee Meeting Minutes

Meeting Date	Thursday, July 10, 2025
Meeting Time	12:04 PM – 2:02 PM
Meeting Type	Teams Meeting
IBC Members Present	1. Caroline Westwater, Ph.D., (IBC Chair) 2. John Woodward, Ph.D. (IBC Vice Chair) 3. Christina Voelkel-Johnson, Ph.D., (BSO) 4. Arabinda Das, Ph.D., (IBC Member) 5. Lisa Steed, Ph.D., (IBC Member) 6. Alicia Braxton Hickman, DVM, Ph.D., DACLAM (IBC Member / Veterinary Medical Officer) 7. Diane Lauritsen, Ph.D., (Local Non-affiliated Member) 8. Ana Zimmerman, Ph.D. (Local Non-affiliated Member)
Quorum	Number of Members Present (Voting):8 Number of Members Not Present:2 Late Arrival of Voting Members:0 Early Departure of Voting Members:0
Other Individuals in Attendance	Michael Smith, Ph.D., (IBC Manager) Gloriane Schnabolk Ph.D., (IACUC & IBC Senior Administrator)
Call to Order	The IBC Chair called the meeting to order at 12:04 PM
Conflicts of Interests	The IBC Chair reminded all members present to identify any conflicts of interest before each registration is reviewed.
Review and Approval of Previous Meeting Minutes	Date of meeting minutes approved: May 8, 2025 Motion to approve the minutes as written. Voting: (Total =8, For =8, Opposed =0, Abstain = 0).
Review of Prior Business	Discussed the development of a RedCap self-assessment form for compliance with the Executive Order of May 5, 2025. Discussed NOT-OD-25-082: Promoting Maximal Transparency Under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules
New IBC Registration and Amendments for Review (repeat for each registration)	

Protocol #	IBC-25-253
PI Name	Yao, Hai

Formatted: Font: 11 pt, Font color: Auto

Study Title	Establishment of Stable Fluorescently Labeled Cell Lines for Visualization and Tracking of Mitochondrial Transfer Between Chondrocytes and Endothelial Cells		
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other		
rDNA Category	III-D1a		
Genetically modified microbes or vectors	Lentiviral vector		
Transgene expression	mito-Dendra2, mCherry		
Highest BSL	BSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ BSC Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-261
PI Name	Hartman, Jessica
Study Title	Generating CRISPR/Cas9-edited CYP2E1-flox and KO mice with the TGE Core
Agent	☒ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes

	☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D4b, III-E-3
Genetically modified microbes or vectors	N/A
Transgene expression	Cyp2E1
Highest BSL	BSL1, ABSL1
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☒ BSL1 ☐ BSL2 ☒ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Woodward
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-260
PI Name	Patterson, Logan
Study Title	Remnant Respiratory Specimens Biobanking
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☒ Other: RG2 bacterial isolates
rDNA Category	N/A
Genetically modified microbes or vectors	N/A

Transgene expression	N/A
Highest BSL	BSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Woodward
Votes			
For:7	Against:0	Abstained:1	Recused:0

Protocol #	IBC-25-245
PI Name	Jiang, Wei
Study Title	Investigating HIV pathogenesis using EcoHIV infected mice
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☒ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D4b
Genetically modified microbes or vectors	EcoHIV
Transgene expression	MLV gp80, GFP, luciferase
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒

	Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Steed	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-244
PI Name	Carroll, Steven
Study Title	Comparative Oncogenomics for Peripheral Nerve Sheath Cancer Gene Discovery
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☒ Gene modified mouse cells ☒ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D4b
Genetically modified microbes or vectors	Adenoviral and Lentiviral vectors
Transgene expression	Cre recombinase, H2B-mCherry, bTubulin-EYFP, Erbb4 p.Ile712Met and Erbb4 p.Arg927Gln, VCP, NF1, GFP
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐
Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☒ Conditional approval with subcommittee post-review

First:	Voelkel-Johnson	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-268		
PI Name	Tsao, Betty		
Study Title	Generating [redacted] with TGE core		
Agent	☒ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other		
rDNA Category	III-D1a, III-E-3		
Genetically modified microbes or vectors	N/A		
Transgene expression	Slc7a7		
Highest BSL	BSL1, ABSL1		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☐ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-266
PI Name	Zhai, Yuan
Study Title	Liver Immune Responses against Ischemia-Reperfusion
Agent	☐ Plasmid DNA/mRNA

	☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☒ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	N/A
Genetically modified microbes or vectors	N/A
Transgene expression	N/A
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☐ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Das
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-262
PI Name	Smith, Alexander
Study Title	Discovery of novel pharmacotherapeutic targets for opioid addiction
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells

	☐ Other
rDNA Category	I III-D1a, III-D4b
Genetically modified microbes or vectors	AAV
Transgene expression	ChR2, eNpHR, EYFP/mCherry/GCaMP, Cre recombinase, Flp recombinase
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-258
PI Name	Mei, Ying
Study Title	COVID-19 Biorepository, Ying Mei, Serum and Blood samples
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☒ Other: human-derived substances/patient samples
rDNA Category	N/A
Genetically modified microbes or vectors	N/A
Transgene expression	N/A
Highest BSL	BSL2
Training	☒ Complete ☐ Pending

Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-242
PI Name	Zhang, Hailong
Study Title	Bacterial Pathogens and Toxins in Murine Infection Models
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☒ RG2 microbes ☒ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D4b
Genetically modified microbes or vectors	Salmonella Typhimurium, Listeria monocytogenes, Vibrio cholerae: Cholera toxin, Citrobacter rodentium:
Transgene expression	GFP
Highest BSL	BSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Steed
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-262
PI Name	Han, Lu
Study Title	Interactions between tumor cells and stromal cells
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☒ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other: human-derived substances/patient samples
rDNA Category	III-D1a, III-D4b
Genetically modified microbes or vectors	Lentiviral vector
Transgene expression	GATA6, FOXF1, and FOXF2. Luciferase
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Zimmerman
Votes			
For:8	Against:0	Abstained:0	Recused:0

Meeting Adjournment	The IBC Chair called for the meeting to be adjourned at 2:02 PM